Abstract

The invention relates to compounds of formula: The invention relates to compounds of formula: The invention relates to compounds of formula: in which X, Y, L and Ln3+ are as defined in the description.

IPC Classes  ?

• C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table

Abstract

The invention relates to a novel method for determining the binding of an antibody to the complement component 1q (C1q). The process according to the invention makes it possible to measure the binding of an antibody to the C1q in a Homogeneous Proximity Assay (HAS).

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching

Abstract

The invention relates to a compound of formula (I) wherein R1; R2, R3 and R4 are as defined in the description. The invention also relates to europium (III) complexes obtained from a compound of formula (I), or from a complexing agent including said compound, and to the use of such complexes to label organic or biological molecules. The invention relates to a compound of formula (I) wherein R1; R2, R3 and R4 are as defined in the description. The invention also relates to europium (III) complexes obtained from a compound of formula (I), or from a complexing agent including said compound, and to the use of such complexes to label organic or biological molecules.

IPC Classes  ?

• C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table
• G01N 33/84 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving inorganic compounds or pH

Abstract

The invention relates to antibodies or antibody fragments capable of binding to G-protein alpha, nucleic acid sequences coding for the antibody, vectors comprising the nucleic acid sequence, cells comprising the vector or the nucleic acid sequence and a kit-of-parts comprising (i) the antibody or antibody fragment or the composition and (ii) a source of GTP labeled with a member of a pair of RET partners.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The invention relates to complexing agents of formula (I): 3 are as defined in the description. The invention also relates to lanthanide complexes obtained from these complexing agents.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table

Abstract

The invention relates to a novel method for determining the binding of an antibody to the complement component 1q (C1q). The process according to the invention makes it possible to measure the binding of an antibody to the C1q in a Homogeneous Proximity Assay (HAS).

IPC Classes  ?

• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to compounds of formula: 3+ are as defined in the description.

IPC Classes  ?

• C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table

Abstract

12344 are as defined in the description. The invention also relates to europium (III) complexes obtained from a compound of formula (I), or from a complexing agent including said compound, and to the use of such complexes to label organic or biological molecules.

IPC Classes  ?

• C07D 213/36 - Radicals substituted by singly-bound nitrogen atoms
• C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The invention relates to a method for determining the ability of a molecule to modulate the activation of a G protein-coupled receptor (GPCR), said method comprising the following steps: a) introducing, in a first container: a membrane preparation bearing one or more GPCRs and one or more alpha G-proteins, a source of nonhydrolyzable or slowly hydrolyzable GTP labeled with a first member of a pair of RET partners, a ligand of the alpha subunit of a G protein (alpha G-protein) labeled with a second member of the pair of RET partners, said ligand being capable of binding to the full alpha G-protein bound to the nonhydrolyzable or slowly hydrolyzable GTP labeled with the first member of a pair of RET partners, optionally a GPCR agonist; b) measuring the RET signal emitted in the first container; c) introducing (i) in a second container, the same reagents as in step a) and the molecule to be assayed or (ii) in the first container, the molecule to be assayed; d) measuring the RET signal emitted in the second container or in the first container obtained in step c); e) comparing the signals obtained in steps b) and d), a modulation of the signal obtained in step d) relative to that obtained in step b) indicating that the molecule to be tested is capable of modulating the activation of the GPCR.

IPC Classes  ?

• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching

Abstract

in-vitroin-vitro method for detecting in a sample a β-sheet aggregate form of a protein forming β-sheet aggregates (ΡΑΡβ), comprising a step of adjusting the pH of a sample likely to contain ΡΑΡβ at a pH ranging from 9.7 to 13.2 in order to separate out all or one portion of the ΡΑΡβ in order to obtain a β-sheet non-aggregate form of the protein forming β-sheet aggregates (ΡΝΑΡβ) and measuring the ΡΝΑΡβ content with an appropriate immunological method at a pH ranging from 6 to 9.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to antibodies or an antibody fragment capable of binding to G-protein alpha, to nucleic acid sequences encoding the antibody, to vectors comprising the nucleic acid sequence, to cells comprising the vector or the nucleic acid sequence and to a reagent kit comprising (i) the antibody or the antibody fragment or the composition and (ii) a source of GTP labelled with a member of a pair of RET partners.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
• G01N 33/577 - ImmunoassayBiospecific binding assayMaterials therefor involving monoclonal antibodies
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes

Abstract

The invention concerns a method for determining the ability of a molecule to modulate the activation of a G protein-coupled receptor (GPCR), the method comprising the following steps: a) introducing, into a first container: - a membrane preparation bearing one or more GPCR(s) and one or more Galpha protein(s), - a source of non-hydrolysable or slowly hydrolysable GTP labelled by a first member of a pair of RET partners, - a ligand of the alpha sub-unit of a G protein (Galpha protein) labelled by a second member of the pair of RET partners, the ligand being capable of binding with the full Galpha protein bound to the non-hydrolysable or slowly hydrolysable GTP labelled by the first member of a pair of RET partners, - optionally, a GPCR agonist; b) measuring the RET signal emitted in the first container; c) introducing, (i) into a second container, the same reagents as in step a) and the molecule to be tested or, (ii) into the first container, the molecule to be tested; d) measuring the RET signal emitted in the second container or in the first container obtained in step c); e) comparing the signals obtained in steps b) and d), a modulation in the signal obtained in step d) relative to that obtained in step b) indicating that the molecule to be tested is capable of modulating the activation of the GPCR.

IPC Classes  ?

• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent

Abstract

The invention relates to compounds of formula (I), in which X, Y, L and Ln3+ are as defined in the description.

IPC Classes  ?

• C07H 23/00 - Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
• G01N 33/20 - Metals

Abstract

The invention relates to a single-domain antibody (sdAb) that binds to the G alpha protein and comprises an amino acid sequence which consists of 3 CDR regions (CDR1 to CDR3) and 4 hinge regions (FR1 to FR4), has the following formula (I): FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (I), and advantageously has a dissociation constant (Kd), measured by FRET, of less than 100 nM.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention relates to a method for determining the ability of a molecule to modulate the activity of a G protein-coupled receptor (GPCR), said method comprising the following steps: a) introducing, into a first container: - a first membrane preparation bearing one or more GPCRs and one or more G protein(s), - a source of GDP or a source of GTP, - a first ligand of the alpha subunit of a G protein (Galpha protein) labelled with a first member of a pair of RET partners, and a second ligand of the Galpha protein labelled with a second member of the pair of RET partners, said ligands being able to specifically bind, either individually or in combination, to the empty Galpha protein or to the full Galpha protein; b) measuring the RET signal emitted in the first container; c) introducing (i) into a second container, the same reactants as in step a) and the molecule to be tested or (ii) into the first container, the molecule to be tested; d) measuring the RET signal emitted in the second container or in the first container obtained in step c); e) comparing the signals obtained in steps b) and d).

IPC Classes  ?

• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent

Abstract

The invention relates to complexing agents of formula (I) 1 are as defined in the description. The invention also relates to lanthanide complexes obtained from said complexing agents. The invention can be used for marking biological molecules.

IPC Classes  ?

• C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table
• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

The invention relates to complexing agents of formula (I), in which chromium1, chromium2 and chromium3 are as defined in the description. The invention also relates to lanthanide complexes that are obtained from said complexing agents. The invention can be used for marking biological molecules.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
• C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The invention relates to complexing agents of formula (I), in which Ra, chromium 1, chromium2, and chromium 3 are as defined in the description. The invention also relates to lanthanide complexes that are obtained from said complexing agents. The invention can be used for marking biological molecules.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07F 9/30 - Phosphinic acids [R2=P(:O)OH]Thiophosphinic acids
• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper

Abstract

The invention relates to complexing agents of formula (I), in which A1, A2, A3 and R1 are as defined in the description. The invention likewise relates to lanthanide complexes obtained from said complexing agents. The invention can be used for marking biological molecules.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
• C07F 3/00 - Compounds containing elements of Groups 2 or 12 of the Periodic Table

Goods & Services

Consultancy relating to the establishment and running of businesses; Planning concerning business management, namely, searching for partners for amalgamations and business take-overs as well as for business establishments; Business networking services; Business expertise services; Consultancy relating to business management and direction; Business analysis, research and information services; Providing of commercial information and data; Providing of commercial statistical information in the medical, pharmaceutical and biotechnology field; Consultancy and advisory services in the field of business strategy; Marketing assistance; Business risk assessment services; All the aforesaid services being provided in the pharmaceutical and biotechnology field; Professional networking in the field of technological, scientific, medical, pharmacological and biotechnological research. Financial services provided to partnerships; Raising of funds for financial purposes; Providing funding for the development of new technology; Consultancy services relating to corporate finance; Facilitating and arranging financing; Financial nominee services; Financial evaluation; Financial risk assessment services; Investment risk assessment services; Financial assessment of intellectual and industrial property; All the aforesaid services being provided in the pharmaceutical and biotechnology field. Providing of training and tuition; Tutoring; Mentoring (providing of training); Coaching [training]; All the aforesaid services being provided in the pharmaceutical and biotechnology field. Providing of technological and scientific research services; Providing of research facilities; Providing of research laboratories; Providing of information relating to technological, scientific, medical, pharmaceutical and biotechnological research; Testing, analysis and evaluation of the goods and services of others for the purpose of certification; Analysis and evaluation of product development; Analysis and evaluation of product design; Assessments in the fields of science and technology, provided by engineers; Consultancy relating to biotechnology; Research and development in the pharmaceutical and biotechnology fields; Consultancy relating to pharmaceutical and biotechnological research and development; All the aforesaid services being provided in the pharmaceutical and biotechnology field; Providing of medical and pharmaceutical research laboratories. Services for the provision of medical facilities; Providing of medical and pharmaceutical information; Pharmaceutical advice; All the aforesaid services being provided in the pharmaceutical and biotechnology field. Legal services; Legal assistance in the drawing up of contracts; Services in the field of intellectual and industrial property; Management of intellectual and industrial property rights; Providing of information in the field of intellectual and industrial property; Legal services relating to the negotiation and drafting of contracts in the field of intellectual and industrial property rights; Legal services relating to company formation and registration; Licensing of intellectual and industrial property rights; All the aforesaid services being provided in the pharmaceutical and biotechnology field.

Abstract

The invention relates to a method for quantifying a protein of interest present in a biological sample containing cells. Said sample is contained in a measurement medium. Said method involves measuring, in addition to the protein of interest, a reference protein, the expression level of which is relatively constant from one cell to another or from one cell type to another. The invention also relates to a kit and a fluorimeter for implementing said method.

IPC Classes  ?

• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching

Abstract

The present invention relates to anti- metabotropic glutamate receptor subtype 2 (mGluR2) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The invention relates to complexing agents of formula (I): in which A, chrom1, chrom2 and chrom3 are as defined in the description. The invention also relates to the lanthanide complexes obtained from these complexing agents.

IPC Classes  ?

• C07D 255/02 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups not condensed with other rings
• C07F 9/32 - Esters thereof
• C07D 473/18 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
• C07F 9/58 - Pyridine rings
• C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
• C07D 213/79 - AcidsEsters
• C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table
• C07H 23/00 - Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials

Abstract

The present invention relates to anti-Epidermal Growth Factor Receptor (EGFR) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention relates to a method for detecting the binding of an antibody to an Fc receptor present on the surface of a cell as well as to a method for determining the level of glycosylation of an antibody. The invention also relates to a reagent kit for carrying out these methods.

IPC Classes  ?

• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

5 are as defined in the description. The invention also concerns lanthanide complexes comprising said complexing agents, as well as a method for synthesizing said agents.

IPC Classes  ?

• C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table
• C07D 255/02 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups not condensed with other rings
• C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 409/08 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
• C07D 401/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

The invention relates to complexing agents of formula (I) where A, chrom1, chrom2 and chrom3 are such as defined in the description. The invention also relates to lanthanide complexes resulting from said complexing agents.

IPC Classes  ?

• C07F 9/30 - Phosphinic acids [R2=P(:O)OH]Thiophosphinic acids
• C07D 255/02 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups not condensed with other rings
• C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
• C07D 473/18 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
• C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table
• A61K 49/00 - Preparations for testing in vivo
• G01N 33/533 - Production of labelled immunochemicals with fluorescent label

Abstract

The invention relates to compounds of formula (I); wherein A and L are as defined in the description. The invention also relates to immunogens obtained from said compounds, and to antibodies raised against said immunogens. The compounds of the invention are used to detect M6G in biological fluids.

IPC Classes  ?

• G01N 33/94 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving narcotics
• C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
• C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere

Abstract

The present invention relates to an ex vivo method for determining the susceptibility of a patient suffering from cancer to respond to a therapeutic treatment based on the administration of an antibody specific for the HER2 protein, this method comprising the quantification of HER2-HER2 dimers in a tissue sample from said patient using the FRET technique. The invention also relates to a kit of reagents for implementing this method.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones

Goods & Services

Chemical products for use in research, industry and manufacturing; reagents for detecting biomolecules or biomolecular interactions in the field of life science research; reagents for detecting biomolecules or biomolecular interactions in the field of life science research, for in-vitro use; fluorescent reagents for measuring biomolecules or biomolecular interactions in the field of life science research, for in-vitro use.

Abstract

The invention relates to a method for determining the ability of a candidate antibody to keep a first cell and a second cell close to one another, said method comprising the following steps: putting said candidate antibody into contact with (i) a first cell exhibiting within the extracellular part of its plasma membrane a first protein which is known or suspected to be recognized by the candidate antibody and (ii) a second cell exhibiting within the extracellular part of the plasma membrane a second protein which is known or suspected to also be recognized by the candidate antibody, each of the proteins being marked by a member of a pair of FRET partners, and measuring the FRET signal and comparing it with the measured signal in the absence of the candidate antibody. The invention also relates to the reagents needed to implement this method.

IPC Classes  ?

• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Goods & Services

Chemical preparations for use in scientific research, industry and general industrial manufacturing; biochemical reagents for non-medical purposes, namely, for detecting biomolecules or biomolecular interactions in the field of life science research; biochemical reagents for non-medical purposes, namely, for detecting biomolecules or biomolecular interactions in the field of life science research, for in-vitro research use; biochemical reagents for non-medical purposes, namely, fluorescent reagents for measuring biomolecules or biomolecular interactions in the field of life science research, for in-vitro research use

Abstract

The subject matter of the invention is a method for measuring the luminescence of a long-life fluorescent compound present in a measuring medium, said medium containing a biological sample, characterised in that it comprises the following steps: a) introduction of a long-life fluorescent compound into the measuring medium, b) introduction, into the measuring medium, of a fluorescent marking agent, the absorption spectrum of which allows the excitation thereof at the same wavelength as that used to excite the long-life fluorescent compound, wherein said emission spectrum allows the measurement of the luminescence thereof at the same wavelength as that used to measure the luminescence of the long-life fluorescent compound, c) excitation of the measuring medium with a wavelength corresponding to an absorption peak of the long-life fluorescent compound, d) measurement of the luminescence emitted by the measuring medium immediately after excitation of said medium, mainly corresponding to the luminescence of the marking agent, and for a period of 5 ns to 45 ps, at a wavelength corresponding to an emission peak of the long-life fluorescent compound, e) time-resolved measurement of the luminescence emitted by the measuring medium at the same wavelength as that used in step d), after a delay of 20 to 200 ps following the excitation of the measuring medium and for a period of 200 to 1000 ps, said luminescence mainly corresponding to that of the long-life fluorescent compound, f) calculation of a normalised luminescence signal corresponding to the ratio: (signal obtained in step e) / (signal obtained in step d).

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching

Abstract

The invention relates to a method for determining if a patient is at risk of increased mortality, said method comprising the step of measuring the level of vasostatin-1 in a biological sample obtained from said patient. The invention also relates to a sandwich immunoassay kit for implementing said method.

IPC Classes  ?

• G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones

Goods & Services

Chemicals used in research, industry and manufacturing; Reagents for the detection of biomolecules or biomolecular interactions in the field of life sciences research; Reagents for the detection of biomolecules or biomolecular interactions in the field of life sciences research, for in vitro use; Fluorescent reagents for the measurement of biomolecules or biomolecular interactions in the field of life sciences research, for in vitro use.

Abstract

The invention relates to a method for detecting the binding of an antibody to an Fc receptor present on the surface of a cell and a method for determining the level of glycosylation of an antibody. The invention also relates to a reagent kit for implementing said methods.

IPC Classes  ?

• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching

Abstract

The aim of the present invention is to produce complexing agents of formula (I), in which a, b, c, Chrom1, Chrom2, Chrom3, R3, R4 and R5 are as defined in the description. The invention also concerns lanthanide complexes comprising said complexing agents, as well as a method for synthesising said agents.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The invention relates to a method for quantifying a protein expressed at the surface of a cell or present in a tissue sample, said method comprising the use of two ligands capable of binding specifically to a domain of said protein.

IPC Classes  ?

• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Goods & Services

Chemicals for use in research, industry and manufacturing; reagents for detecting biomolecules or biomolecular interactions in connection with life science research; reagents for detecting biomolecules or biomolecular interactions in connection with life science research, for in vitro use; fluorescent reagents for measuring biomolecules or biomolecular interactions in connection with life science research, for in vitro use.

Goods & Services

Chemicals used in research, industry and manufacturing; Reagents for the detection of biomolecules or biomolecular interactions in the field of life sciences research; Reagents for the detection of biomolecules or biomolecular interactions in the field of life sciences research, for in vitro use; Fluorescent reagents for the measurement of biomolecules or biomolecular interactions in the field of life sciences research, for in vitro use.

Goods & Services

Chemical and biochemical reagents for use in scientific research, namely chemical and biochemical reagents for protein labelling to be used in life science and drug screening research; fluorescent compounds for protein labelling. Scientific and technical consulting and research services for the pharmaceutical industry, namely scientific and technical consulting and research services relating to protein labelling to conduct life science and drug screening research.

Goods & Services

Chemical and biochemical reagents for use in scientific research, namely, chemical and biochemical reagents for protein labelling to be used in life science and drug screening research; Chemical reagents, namely, fluorescent dyes for labeling proteins for scientific and research use Scientific and technical consulting and research services for the pharmaceutical industry, namely, scientific and technical consulting and research services relating to protein labelling to conduct life science and drug screening research

Goods & Services

Chemical and biochemical reagents for use in scientific research, namely chemical and biochemical reagents for protein labelling to be used in life science and drug screening research; fluorescent compounds for protein labelling. Scientific and technical consulting and research services for the pharmaceutical industry, namely scientific and technical consulting and research services relating to protein labelling to conduct life science and drug screening research.

Goods & Services

Medical diagnostic testing kits containing diagnostic reagents designed for use in clinical and medical laboratories, for the diagnosis, screening or monitoring of tumors, organ dysfunction, multiple organ failure, sepsis and systemic inflammatory response; medical diagnostic test kits to be used by staff of clinical and medical laboratories for the diagnosis, screening or monitoring of tumors, of organ dysfunction, multiple organ failure, sepsis and systemic inflammatory response, comprising one or several tubes or plates, antibodies, a tracer compound and lyophilisates used to reconstitute control solutions; medical diagnostic test kits for the immunoassay of human chromogranin A in serum or plasma to be used by staff of clinical and medical laboratories.

Goods & Services

Medical diagnostic testing kits containing diagnostic reagents designed for use in clinical and medical laboratories, for the diagnosis, screening or monitoring of tumors, organ dysfunction, multiple organ failure, sepsis and systemic inflammatory response; medical diagnostic test kits to be used by staff of clinical and medical laboratories for the diagnosis, screening or monitoring of tumors, of organ dysfunction, multiple organ failure, sepsis and systemic inflammatory response, comprising one or several tubes or plates, antibodies, a tracer compound and lyophilisates used to reconstitute control solutions; medical diagnostic test kits for the immunoassay of human chromogranin A in serum or plasma to be used by staff of clinical and medical laboratories

Goods & Services

Medical diagnostic testing kits containing diagnostic reagents designed for use in clinical and medical laboratories, for the diagnosis, screening or monitoring of tumors, organ dysfunction, multiple organ failure, sepsis and systemic inflammatory response; medical diagnostic test kits to be used by staff of clinical and medical laboratories for the diagnosis, screening or monitoring of tumors, of organ dysfunction, multiple organ failure, sepsis and systemic inflammatory response, comprising one or several tubes or plates, antibodies, a tracer compound and lyophilisates used to reconstitute control solutions; medical diagnostic test kits for the immunoassay of human chromogranin A in serum or plasma to be used by staff of clinical and medical laboratories.

Goods & Services

Chemical products for use in industry; chemicals for use in science; chemical preparations for use in scientific research; chemical reagents (other than for medical or veterinary purposes). Pharmaceutical preparations; therapeutic and diagnostic radiopharmaceutical products; chemico-pharmaceutical preparations; products intended for the implementation of biological/biochemical doses for in vitro diagnosis, for medical use; reagents for medical purposes. Medical apparatus and instruments; apparatus for the administration of radiopharmaceutical products; elution and handling boxes for radio-isotope generators. Scientific services for the pharmaceutical industry and research and design relating thereto; pharmaceutical, chemical and biochemical dosage research and development services.

Goods & Services

Reagents and tests for medical diagnosis designed for use in clinical and medical laboratories, in particular in screening for inflammatory diseases, as well as monitoring patients previously diagnosed as suffering from these diseases; medical test kits to be used by staff of clinical and medical laboratories for medical diagnosis, screening and monitoring of inflammatory diseases, comprising one or several tubes, antibodies, a tracer compound and lyophilisates used to reconstitute control solutions.

Goods & Services

Chemical preparations for use in scientific research, namely fluorescent reagents for in-vitro measurement of biomolecular interactions and for in-vitro drug screening research and antibody reagents used for in-vitro detection of antigens in cell and tissue Products intended for the implementation of biological/biochemical assays for in vitro diagnosis, namely immunoassay kits for use by clinical laboratories, containing labelled antibodies or antigen for in vitro diagnosis of cancer, infection, inflammation, auto-immune, cardiovascular and nervous system diseases Elution and handling boxes for radio-isotope generators, namely apparatus for production and elution of sterile 99m technetium solution to be used in hospitals and radiopharmacies and containers specifically designed for transporting and holding radio-isotope generators Scientific services for the pharmaceutical industry and research and design relating thereto, namely scientific and technical consulting and research services relating to the development of drug screening bioassays for use by research laboratories

Goods & Services

Medical diagnostic testing kits containing diagnostic reagents and tests for medical diagnosis designed for use in clinical and medical laboratories for screening for inflammatory diseases and monitoring patients previously diagnosed as suffering from these diseases; medical diagnostic test kits to be used by staff of clinical and medical laboratories for medical diagnosis, screening and monitoring of inflammatory diseases, comprising one or several tubes, antibodies, a tracer compound and lyophilisates used to reconstitute control solutions

Goods & Services

Chemical products for use in industry; Chemicals for use in science; chemical preparations for use in scientific research; chemical reagents (other than for medical or veterinary purposes). Pharmaceutical preparations; therapeutic and diagnostic radiopharmaceutical products; chemico-pharmaceutical preparations; products intended for the implementation of biological/biochemical doses for in vitro diagnosis, for medical use; Reagents for medical purposes. Medical apparatus and instruments; apparatus for the administration of radiopharmaceutical products; elution and handling boxes for radio-isotope generators. Scientific services for the pharmaceutical industry and research and design relating thereto; pharmaceutical, chemical and biochemical dosage research and development services.

Goods & Services

Medical diagnostic reagents and tests for clinical and medical laboratories, in particular used in screening for inflammatory illnesses as well as for following up patients who have previously been diagnosed with such illnesses; medical analysis kits for clinical and medical laboratory personnel for medical diagnosis of, screening for and following up of inflammatory illnesses, consisting of one or more tubes, antibodies, tracer compounds and lyophilisates for reconstituting standard solutions.

Goods & Services

Chemical products for industrial use, chemical products for scientific use; chemical products for use in research; reagents; reagents for research purposes. Reagents for medical use; reagents in vitro diagnosis. Scientific services for researching molecules for use in the pharmaceutical industry, agri-food industry, agrochemical industry and in the environment sector.

Goods & Services

Chemical products for use in industry; chemicals used in science; research chemicals; reagents for research use. Reagents for medical purposes; reagents for in-vitro diagnostic use. Scientific apparatus and instruments suitable for use with laboratory reagents; fluorometers. Scientific and industrial research.

Goods & Services

FLUORESCENT REAGENTS FOR THE MEASUREMENT OF BIOMOLECULAR INTERACTIONS IN THE FIELD OF LIFE SCIENCE RESEARCH

Goods & Services

Chemical products for use in research, industry and manufactures; reagents for the mesurement of biomolecular interactions in the field of life science research; fluorescent reagents for the measurement of biomolecular interactions in the field of life science research; fluorescent reagents for the measurement of biomolecular interactions in life science research, for in vitro use; tagged binding members, antibodies, monoclonal antibodies, tagged antibodies, tagged monoclonal antibodies, and reagents for use therewith. Chemical products for use in research, industry and manufactures; reagents for the measurement of biomolecular interactions in the field of life science research; fluorescent reagents for the measurement of biomolecular interactions in the field of life science research; fluorescent reagents for the measurement of biomolecular interactions in life science research, for in vitro use; tagged binding members, antibodies, monoclonal antibodies, tagged antibodies, tagged monoclonal antibodies, and reagents for use therewith.

Goods & Services

Produits chimiques destinés à l'industrie; produits chimiques destinés aux sciences; produits chimiques destinés à la recherche; réactifs; réactifs pour la recherche. Réactifs à usage médical; réactifs pour le diagnostic in-vitro. Appareils et instruments scientifiques capables d'utiliser les réactifs du laboratoire; fluoromètre. Appareils et instruments d'analyse et/ou d'immunoanalyse. Services dans la recherche scientifique et industrielle.

Goods & Services

Produits chimiques destinés à l'industrie et aux sciences; réactifs pour la recherche. Réactifs pour le diagnostic in vitro. Appareils et instruments scientifiques capables d'utiliser les réactifs du laboratoire; fluoromètres. Appareils et instruments d'analyse et/ou d'immuno-analyse. Services dans la recherche scientifique et industrielle.